POOLBEG PHARMA PLC Logo

POOLBEG PHARMA PLC

POLB | IL

Overview

Corporate Details

ISIN(s):
GB00BKPG7Z60
LEI:
213800UZ8WJLWYHBFL52
Country:
United Kingdom
Address:
QUEEN MARY BIOENTERPRISES INNOVATION CENTRE, E1 2AX LONDON
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company that acquires, develops, and commercializes innovative medicines for diseases with high unmet medical needs. The company utilizes a proprietary, AI-led discovery platform that leverages over 20 years of human challenge trial data to identify novel drug targets and treatments. This AI-driven approach aims to accelerate target identification, reduce costs, and increase the probability of clinical success. Key programmes in its pipeline target conditions such as cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic disorders, including an oral encapsulated GLP-1 programme for obesity.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for POOLBEG PHARMA PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-01 17:24
Major Shareholding Notification
Notification of Major Holdings
English 43.8 KB
2025-06-23 15:57
Post-Annual General Meeting Information
Results of GM and AGM Meetings
English 16.0 KB
2025-05-27 08:01
Regulatory News Service
FDA Orphan Drug Designation granted for POLB 001
English 18.0 KB
2025-05-27 08:00
Report Publication Announcement
Annual Report, AGM Notice & Circular
English 16.2 KB
2025-05-23 08:00
Share Issue/Capital Change
Result of upsized oversubscribed BookBuild Offer
English 26.8 KB
2025-03-27 08:00
Regulatory News Service
Conference Participation in March & April 2025
English 15.6 KB
2025-02-21 08:00
M&A Activity
Termination of proposed combination with HOOKIPA
English 16.2 KB
2025-02-18 18:35
Major Shareholding Notification
Holding(s) in Company
English 43.7 KB
2025-02-18 18:04
Major Shareholding Notification
Form 8.3 - Poolbeg Pharma plc
English 52.2 KB
2025-01-30 08:00
Regulatory News Service
Offer Update - Extension to PUSU Deadline
English 27.9 KB
2025-01-17 19:25
Major Shareholding Notification
Replacement - Form 8.3 - Poolbeg Pharma plc
English 52.6 KB
2025-01-17 12:27
Major Shareholding Notification
Form 8.3 - Poolbeg Pharma plc
English 51.3 KB
2025-01-16 14:53
Major Shareholding Notification
Form 8.3 - Poolbeg Pharma plc
English 52.2 KB
2025-01-15 19:04
Major Shareholding Notification
Form 8.3 - Poolbeg Pharma plc
English 52.1 KB
2025-01-14 18:33
Major Shareholding Notification
Form 8.3 - Poolbeg Pharma plc
English 51.3 KB

Automate Your Workflow. Get a real-time feed of all POOLBEG PHARMA PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for POOLBEG PHARMA PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN